Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401326 | 0.77 | TSHR (0.36) | TSHR | |
| SCHEMBL13275969 | 0.73 | TSHR (0.32) | TSHR | |
| SCHEMBL401327 | 0.73 | TSHR (0.32) | TSHR | |
| SCHEMBL16699289 | 0.71 | TSHR (0.31) | TSHR | |
| SCHEMBL16699647 | 0.71 | TSHR (0.31) | TSHR | |
| SCHEMBL26654150 | 0.71 | LMNA (0.34) | TSHR | |
| SCHEMBL30580584 | 0.71 | TSHR (0.31) | TSHR | |
| SCHEMBL23886755 | 0.70 | TSHR (0.30) | TSHR | |
| SCHEMBL16700604 | 0.70 | TSHR (0.30) | TSHR | |
| SCHEMBL29843608 | 0.70 | TSHR (0.30) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12502376-B2 | Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| US-12492210-B2 | Tricyclic compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-12-09 | — | — | US | disclosed |
| US-20250346612-A1 | INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4605409-A2 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250215019-A1 | ORTHOGONAL FUNCTIONALIZATION OF BRIDGE-SUBSTITUTED BCPS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-03 | — | — | US | disclosed |
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11999699-B2 | Substituted pyrazole amides | Grünenthal GmbH (DE) | 2024-06-04 | — | — | US | disclosed |
| WO-2024086814-A2 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2015073763-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12502376-B2 | Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | SERPINA2, SERPINB1, SERPINE1 | TSHR 1925/4885 |
| US-20250346612-A1 | INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES | LSS, PAICS, BLVRB | TSHR 1400/4885 |
| US-11999699-B2 | Substituted pyrazole amides | SCN8A, SCN1A, SCN7A | TSHR 2437/4885 |
| US-20250215019-A1 | ORTHOGONAL FUNCTIONALIZATION OF BRIDGE-SUBSTITUTED BCPS | BMP2, BMP4, DCX | TSHR 3699/4885 |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | TSHR 4305/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | TSHR 3888/4885 |
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | TSHR 3858/4885 |
| US-12492210-B2 | Tricyclic compounds and their use | CYP2C8, CYP11B2, CYP3A7 | TSHR 2802/4885 |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | TSHR 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.